Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Fukuokaya W, Yanagisawa T, Hashimoto M, Yamamoto S, Koike Y, Imai Y, Iwatani K, Onuma H, Ito K, Urabe F, Tsuzuki S, Kimura S, Miki J, Oyama Y, Abe H, Kimura T.
Fukuokaya W, et al. Among authors: miki j.
Cancer Immunol Immunother. 2023 Apr;72(4):841-849. doi: 10.1007/s00262-022-03291-5. Epub 2022 Sep 14.
Cancer Immunol Immunother. 2023.
PMID: 36102985
Free PMC article.